首页|地舒单抗对骨质疏松性椎体压缩性骨折经皮椎体成形术后再发骨折的防治

地舒单抗对骨质疏松性椎体压缩性骨折经皮椎体成形术后再发骨折的防治

扫码查看
目的 探讨地舒单抗对骨质疏松性椎体压缩性骨折经皮椎体成形术后再发骨折的预防效果.方法 选取2022年1月-2022年12月在广州医科大学附属第二医院骨科诊断为骨质疏松性椎体压缩性骨折行经皮椎体成形术治疗的72例患者作为研究对象,按照随机数表法将其分成两组各36例.对照组给予常规抗骨质疏松治疗,观察组在对照组治疗的基础上加用地舒单抗,两组均进行1年随访,比较1年内两组的再骨折率及骨密度(BMD)、疼痛视觉模拟量表(VAS)评分、Oswestry功能障碍指数(ODI)、Beck值、矢状面Cobb角和Ⅰ型前胶原氨基端前肽(PINP)、Ⅰ型胶原羧基端肽β特殊序列(β-CTX)的水平.结果 两组术前BMD、VAS评分、ODI、Beck值、矢状面Cobb角和PINP及β-CTX水平比较,差异均无统计学意义(P>0.05);术后随访6个月,观察组BMD大于对照组(P<0.05),VAS评分、ODI及PINP和β-CTX水平低于对照组(P<0.05);术后随访1年,观察组BMD和Beck值大于对照组(P<0.05),再骨折率、VAS评分、ODI、矢状面Cobb角及PINP和β-CTX水平均低于对照组(P<0.05).结论 地舒单抗治疗可以有效缓解骨质疏松性椎体压缩性骨折患者经皮椎体成形术后的疼痛,促进骨折愈合,增加椎体骨密度,降低椎体再骨折的发生率.
Prevention and treatment of recurrent fractures after percutaneous vertebroplasty with denosumab in patients with osteoporotic vertebral compression fractures
Objective To investigate the preventive effect of denosumab on recurrent fractures after percutaneous vertebro-plasty in patients with osteoporotic vertebral compression fractures.Methods A total of 72 patients diagnosed with osteoporotic verte-bral compression fracture and treated by percutaneous vertebroplasty in the orthopedic department of the Second Affiliated Hospital of Guangzhou Medical University from January 2022 to December 2022 were selected as the study subjects.Patients were randomly divided into two groups,each had 36 cases.The control group received conventional anti-osteoporosis treatment,and the observation group add-ed denosumab on the basis of control group treatment.Both groups were followed for 1 year,while the fracture rate and the levels of bone mineral density(BMD),visual analogue scale(VAS)score,oswestry disability index(ODI),beck value,sagittal cobb angle and procollagen type Ⅰ N-terminal propeptid(PINP)and β-carboxy-terminal cross-linked telopeptide of type Ⅰ collagen(β-CTX)were compared between the two groups.Results There was no significant preoperative on BMD,VAS score,ODI index,beck val-ues,sagittal cobb angle,PINP and β-CTX levels between the two groups before the surgery(P>0.05);After postoperative follow-up of 6 months,BMD in the observation group was higher than that in the control group(P<0.05),while VAS score,ODI index,PINP and β-CTX levels were lower than those in the control group(P<0.05).At 1 year postoperative follow-up,BMD and beck values in the observation group were higher than those in the control group(P<0.05),while fracture rate,VAS score,ODI index,sagittal cobb angle and PINP and β-CTX levels were lower than those in the control group(P<0.05).Conclusion Denosumab treatment effec-tively relieves pain after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures,promotes fracture healing,increases vertebral bone mineral density,and reduces the incidence of vertebral refractures.

DenosumabOsteoporotic vertebral compression fracturesVertebroplasty

向守裕、唐程、凌龙、刘炜、白兵文、曹燕明

展开 >

广州医科大学附属第二医院骨科,广州 510245

地舒单抗 骨质疏松性椎体压缩性骨折 椎体成形术

2025

国际老年医学杂志
吉林大学

国际老年医学杂志

影响因子:0.435
ISSN:1674-7593
年,卷(期):2025.46(1)